Cargando…
Effect of a Fourth Dose of mRNA Vaccine and of Immunosuppression in Preventing SARS-CoV-2 Breakthrough Infections in Heart Transplant Patients
Patients with heart transplantation (HT) have an increased risk of COVID-19 disease and the efficacy of vaccines on antibody induction is lower, even after three or four doses. The aim of our study was to assess the efficacy of four doses on infections and their interplay with immunosuppression. We...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053932/ https://www.ncbi.nlm.nih.gov/pubmed/36985328 http://dx.doi.org/10.3390/microorganisms11030755 |
_version_ | 1785015531295735808 |
---|---|
author | Masetti, Marco Scuppa, Maria Francesca Aloisio, Alessio Giovannini, Laura Borgese, Laura Manno, Stefania Tazza, Beatrice Pascale, Renato Bonazzetti, Cecilia Caroccia, Natascia Sabatino, Mario Spitaleri, Giosafat Viale, Pierluigi Giannella, Maddalena Potena, Luciano |
author_facet | Masetti, Marco Scuppa, Maria Francesca Aloisio, Alessio Giovannini, Laura Borgese, Laura Manno, Stefania Tazza, Beatrice Pascale, Renato Bonazzetti, Cecilia Caroccia, Natascia Sabatino, Mario Spitaleri, Giosafat Viale, Pierluigi Giannella, Maddalena Potena, Luciano |
author_sort | Masetti, Marco |
collection | PubMed |
description | Patients with heart transplantation (HT) have an increased risk of COVID-19 disease and the efficacy of vaccines on antibody induction is lower, even after three or four doses. The aim of our study was to assess the efficacy of four doses on infections and their interplay with immunosuppression. We included in this retrospective study all adult HT patients (12/21–11/22) without prior infection receiving a third or fourth dose of mRNA vaccine. The endpoints were infections and the combined incidence of ICU hospitalizations/death after the last dose (6-month survival rate). Among 268 patients, 62 had an infection, and 27.3% received four doses. Following multivariate analysis, three vs. four doses, mycophenolate (MMF) therapy, and HT < 5 years were associated with an increased risk of infection. MMF ≥ 2000 mg/day independently predicted infection, together with the other variables, and was associated with ICU hospitalization/death. Patients on MMF had lower levels of anti-RBD antibodies, and a positive antibody response after the third dose was associated with a lower probability of infection. In HT patients, a fourth dose of vaccine against SARS-CoV-2 reduces the risk of infection at six months. Mycophenolate, particularly at high doses, reduces the clinical effectiveness of the fourth dose and the antibody response to the vaccine. |
format | Online Article Text |
id | pubmed-10053932 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100539322023-03-30 Effect of a Fourth Dose of mRNA Vaccine and of Immunosuppression in Preventing SARS-CoV-2 Breakthrough Infections in Heart Transplant Patients Masetti, Marco Scuppa, Maria Francesca Aloisio, Alessio Giovannini, Laura Borgese, Laura Manno, Stefania Tazza, Beatrice Pascale, Renato Bonazzetti, Cecilia Caroccia, Natascia Sabatino, Mario Spitaleri, Giosafat Viale, Pierluigi Giannella, Maddalena Potena, Luciano Microorganisms Article Patients with heart transplantation (HT) have an increased risk of COVID-19 disease and the efficacy of vaccines on antibody induction is lower, even after three or four doses. The aim of our study was to assess the efficacy of four doses on infections and their interplay with immunosuppression. We included in this retrospective study all adult HT patients (12/21–11/22) without prior infection receiving a third or fourth dose of mRNA vaccine. The endpoints were infections and the combined incidence of ICU hospitalizations/death after the last dose (6-month survival rate). Among 268 patients, 62 had an infection, and 27.3% received four doses. Following multivariate analysis, three vs. four doses, mycophenolate (MMF) therapy, and HT < 5 years were associated with an increased risk of infection. MMF ≥ 2000 mg/day independently predicted infection, together with the other variables, and was associated with ICU hospitalization/death. Patients on MMF had lower levels of anti-RBD antibodies, and a positive antibody response after the third dose was associated with a lower probability of infection. In HT patients, a fourth dose of vaccine against SARS-CoV-2 reduces the risk of infection at six months. Mycophenolate, particularly at high doses, reduces the clinical effectiveness of the fourth dose and the antibody response to the vaccine. MDPI 2023-03-15 /pmc/articles/PMC10053932/ /pubmed/36985328 http://dx.doi.org/10.3390/microorganisms11030755 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Masetti, Marco Scuppa, Maria Francesca Aloisio, Alessio Giovannini, Laura Borgese, Laura Manno, Stefania Tazza, Beatrice Pascale, Renato Bonazzetti, Cecilia Caroccia, Natascia Sabatino, Mario Spitaleri, Giosafat Viale, Pierluigi Giannella, Maddalena Potena, Luciano Effect of a Fourth Dose of mRNA Vaccine and of Immunosuppression in Preventing SARS-CoV-2 Breakthrough Infections in Heart Transplant Patients |
title | Effect of a Fourth Dose of mRNA Vaccine and of Immunosuppression in Preventing SARS-CoV-2 Breakthrough Infections in Heart Transplant Patients |
title_full | Effect of a Fourth Dose of mRNA Vaccine and of Immunosuppression in Preventing SARS-CoV-2 Breakthrough Infections in Heart Transplant Patients |
title_fullStr | Effect of a Fourth Dose of mRNA Vaccine and of Immunosuppression in Preventing SARS-CoV-2 Breakthrough Infections in Heart Transplant Patients |
title_full_unstemmed | Effect of a Fourth Dose of mRNA Vaccine and of Immunosuppression in Preventing SARS-CoV-2 Breakthrough Infections in Heart Transplant Patients |
title_short | Effect of a Fourth Dose of mRNA Vaccine and of Immunosuppression in Preventing SARS-CoV-2 Breakthrough Infections in Heart Transplant Patients |
title_sort | effect of a fourth dose of mrna vaccine and of immunosuppression in preventing sars-cov-2 breakthrough infections in heart transplant patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053932/ https://www.ncbi.nlm.nih.gov/pubmed/36985328 http://dx.doi.org/10.3390/microorganisms11030755 |
work_keys_str_mv | AT masettimarco effectofafourthdoseofmrnavaccineandofimmunosuppressioninpreventingsarscov2breakthroughinfectionsinhearttransplantpatients AT scuppamariafrancesca effectofafourthdoseofmrnavaccineandofimmunosuppressioninpreventingsarscov2breakthroughinfectionsinhearttransplantpatients AT aloisioalessio effectofafourthdoseofmrnavaccineandofimmunosuppressioninpreventingsarscov2breakthroughinfectionsinhearttransplantpatients AT giovanninilaura effectofafourthdoseofmrnavaccineandofimmunosuppressioninpreventingsarscov2breakthroughinfectionsinhearttransplantpatients AT borgeselaura effectofafourthdoseofmrnavaccineandofimmunosuppressioninpreventingsarscov2breakthroughinfectionsinhearttransplantpatients AT mannostefania effectofafourthdoseofmrnavaccineandofimmunosuppressioninpreventingsarscov2breakthroughinfectionsinhearttransplantpatients AT tazzabeatrice effectofafourthdoseofmrnavaccineandofimmunosuppressioninpreventingsarscov2breakthroughinfectionsinhearttransplantpatients AT pascalerenato effectofafourthdoseofmrnavaccineandofimmunosuppressioninpreventingsarscov2breakthroughinfectionsinhearttransplantpatients AT bonazzetticecilia effectofafourthdoseofmrnavaccineandofimmunosuppressioninpreventingsarscov2breakthroughinfectionsinhearttransplantpatients AT caroccianatascia effectofafourthdoseofmrnavaccineandofimmunosuppressioninpreventingsarscov2breakthroughinfectionsinhearttransplantpatients AT sabatinomario effectofafourthdoseofmrnavaccineandofimmunosuppressioninpreventingsarscov2breakthroughinfectionsinhearttransplantpatients AT spitalerigiosafat effectofafourthdoseofmrnavaccineandofimmunosuppressioninpreventingsarscov2breakthroughinfectionsinhearttransplantpatients AT vialepierluigi effectofafourthdoseofmrnavaccineandofimmunosuppressioninpreventingsarscov2breakthroughinfectionsinhearttransplantpatients AT giannellamaddalena effectofafourthdoseofmrnavaccineandofimmunosuppressioninpreventingsarscov2breakthroughinfectionsinhearttransplantpatients AT potenaluciano effectofafourthdoseofmrnavaccineandofimmunosuppressioninpreventingsarscov2breakthroughinfectionsinhearttransplantpatients |